Articles By Estel Grace Masangkay

  1. Janssen Links With Transposagen To Develop CAR-T Therapies 12/3/2014

    Janssen Biotech and private biotech firm Transposagen Biopharmaceuticals announced that the companies have entered into a research collaboration and global license agreement to jointly develop allogeneic Chimeric Antigen Receptor T-cells (CAR-T) therapies against cancer.

  2. Alexion's Soliris Awarded Orphan Status In Japan For Neuromyelitis Optica 12/3/2014

    Alexion announced that it has received Orphan Drug Designation from Japan's Ministry of Health, Labor, and Welfare (MHLW) for Soliris (eculizumab) as treatment for patients with neurological disorder neuromyelitis optica (NMO).

  3. Researchers Discover Potential New Treatment Method For ALS 12/2/2014

    A team of scientists at Thomas Jefferson University reported their discovery of a new approach to help enhance the efficacy of drugs that target Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

  4. Merck And NewLink Join Forces For Ebola Vaccine Lead 11/26/2014

    Merck announced that it has partnered with NewLink Genetics in an exclusive global license agreement to develop NewLink’s rVSV-EBOV (Ebola) vaccine candidate.

  5. CHMP Backs Genzyme's Cerdelga For Gaucher Disease 11/26/2014

    Sanofi firm Genzyme announced that it has received a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the approval of Cerdelga (eliglustat) for the treatment of Gaucher disease type 1.

  6. AstraZeneca Expands Maryland Biologics Manufacturing Site For $200M 11/26/2014

    British drug maker giant AstraZeneca announced its plans to expand its Frederick, Maryland biologics manufacturing center in order to support its maturing pipeline, 50 percent of which is comprised of biologics.

  7. ChemoCentryx Gets FDA Orphan Status For Kidney Disease Drug 11/25/2014

    Clinical stage biopharmaceutical company ChemoCentryx announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CCX168 as an investigational treatment for atypical Hemolytic Uremic Syndrome (aHUS).

  8. BerGenBio's AML Drug Granted FDA Orphan Status 11/24/2014

    Oncology biopharmaceutical company BerGenBio announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its investigational drug BGB324 as treatment for acute myeloid leukemia (AML).

  9. Roche, Inovio End Pact On Prostate Cancer Drug 11/21/2014

    Inovio Pharmaceuticals announced that it has ended its agreement with biotech giant Roche to jointly develop Inovio’s INO-5150 as immunotherapy for prostate cancer.

  10. Researchers Convert Skin Cells To Replace HD-Damaged Brain Cells 11/20/2014

    A team of researchers at the Washington University School of Medicine in St. Louis reported that they have discovered a way to directly convert human skin cells into a type of brain cell that has been damaged by Huntington’s disease.